Cardiovascular Diseases, Metabolic Disease
Conditions
Keywords
Nuts
Brief summary
Food is emerging as the new medicine. There has been growing evidence of the beneficial effects of foods, including nuts on human health. Modulation of both glucose and insulin are at the heart of reducing the risk of cardiovascular and other metabolic diseases. The contribution that nuts have on human health has been studied extensively and it is well established that the consumption of nuts revealed improvements in both blood glucose profile and reduced the risk of coronary heart diseases. Nuts, such as almonds, are nutrient-dense foods that are particularly rich in a-tocopherol. They are excellent sources of protein (\ 25% of energy) and fibre, low in saturated fatty acid content (4-6%) and high in monounsaturated fatty acids. They also contain significant amounts of essential micronutrients such as folate (B vitamin) and polyphenols. Recently, strong interests on the health effects of nuts improving metabolic syndrome and controlling diabetes has been reported. Preliminary studies have indicated that the inclusion of nuts in the diets of individuals with diabetes and/or metabolic syndrome may improve postprandial glycaemic response, and lipid metabolism in the long run.
Interventions
OTHERGlucose control
50 g glucose dissolved in 250 mL water
OTHERBread control
91.4 g white bread
OTHERAlmond paste
88.7 g white bread and 15 g almond paste
OTHERAlmond paste and inulin
88.7 g white bread, 15 g almond paste and 4 g inulin
OTHERLow dose almond paste and inulin
89.6 g white bread, 10 g almond paste and 3.8 g inulin
Sponsors
Glico Asia Pacific Pte Ltd
Singapore Institute of Food and Biotechnology Innovation
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
MALE
Age
21 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
* Chinese Males * Age: 21-60 years * Body mass index (BMI) between 18 to 25 kg/m2 * Normal blood pressure (\< 140/90 mmHg) * Fasting blood glucose (FBG) \</= 6 mmol/L
Exclusion criteria
* People who have any major organ dysfunction (eg. cardiovascular, respiratory, hepatic, renal, gastrointestinal) that may influence taste, olfaction, appetite, digestion, metabolism, absorption or elimination of test foods, nutraceutical or drug * People who smoke * People with any genetic and/or metabolic diseases (such as diabetes, hypertension etc) * People who have medical conditions and/or taking medications known to affect glycaemia (glucocorticoids, thyroid hormones, thiazide diuretics) * People with known glucose-6-phosphate dehydrogenase deficiency (G6PD deficiency) * People who have any severe food allergy (e.g. anaphylaxis to peanuts) or any known food allergy/intolerance * People who consume fibre supplements or other supplements that is likely to interfere with study outcomes •• People who have active Tuberculosis (TB) or currently receiving treatment for TB * People who have any known Chronic infection or known to suffer from or have previously suffered from or is a carrier of Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Human Immunodeficiency Virus (HIV) * People who is a study team member or an immediate family of any study team member. Immediate family member is defined as a spouse, parent, child, or sibling, whether biological or legally adopted. * People is enrolled in a concurrent research study judged not to be scientifically or medically compatible with the study of the CNRC. * People who have intentionally restrict food intake * People who have poor veins impeding venous access * People who have any history of severe vasovagal syncope (blackouts or near faints) following blood draws * People who partake in sports at the competitive and/or endurance levels
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Postprandial glucose response | 0, 15, 30, 45, 60, 90, 120, 150, 180 minutes |
| Postprandial insulin response | 0, 15, 30, 45, 60, 90, 120, 150, 180 minutes |
| GI calculation for the composite meal | 0, 15, 30, 45, 60, 90, 120, 150, 180 minutes |
Secondary
| Measure | Time frame |
|---|---|
| Postprandial low-density lipoprotein cholesterol (LDL) level | 0, 15, 30, 45, 60, 90, 120, 150, 180 minutes |
| Postprandial triglyceride level | 0, 15, 30, 45, 60, 90, 120, 150, 180 minutes |
| Postprandial high-density lipoprotein cholesterol (HDL) level | 0, 15, 30, 45, 60, 90, 120, 150, 180 minutes |
| Postprandial total cholesterol (TC) level | 0, 15, 30, 45, 60, 90, 120, 150, 180 minutes |
Countries
Singapore
Outcome results
None listed